These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36386456)

  • 1. Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO.
    Grohé C; Wehler T; Dechow T; Henschke S; Schuette W; Dittrich I; Hammerschmidt S; Müller-Huesmann H; Schumann C; Krüger S; Atz J; Kaiser R
    Transl Lung Cancer Res; 2022 Oct; 11(10):2010-2021. PubMed ID: 36386456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study.
    Grohé C; Blau W; Gleiber W; Haas S; Hammerschmidt S; Krüger S; Müller-Huesmann H; Schulze M; Wehler T; Atz J; Kaiser R
    Clin Oncol (R Coll Radiol); 2022 Jul; 34(7):459-468. PubMed ID: 35012901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
    Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
    Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
    Dhillon S
    Target Oncol; 2015 Jun; 10(2):303-10. PubMed ID: 25894578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis.
    Ljubicic L; Janzic U; Unk M; Terglav AS; Mohorcic K; Seiwerth F; Bitar L; Badovinac S; Plestina S; Korsic M; Kukulj S; Samarzija M; Jakopovic M
    Radiol Oncol; 2023 Sep; 57(3):397-404. PubMed ID: 37665737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.
    Riudavets M; Bosch-Barrera J; Cabezón-Gutiérrez L; Diz Taín P; Hernández A; Alonso M; Blanco R; Gálvez E; Insa A; Mielgo X; Morán T; Ponce S; Roa D; Sánchez JM; Majem M
    Clin Transl Oncol; 2021 Dec; 23(12):2560-2567. PubMed ID: 34292495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy.
    Reck M; Syrigos K; Miliauskas S; Zöchbauer-Müller S; Fischer JR; Buchner H; Kitzing T; Kaiser R; Radonjic D; Kerr K
    Lung Cancer; 2020 Oct; 148():159-165. PubMed ID: 32927350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
    Hanna NH; Kaiser R; Sullivan RN; Aren OR; Ahn MJ; Tiangco B; Voccia I; Pawel JV; Kovcin V; Agulnik J; Gaschler-Markefski B; Barrueco J; Sikken P; Schloss C; Kim JH;
    Lung Cancer; 2016 Dec; 102():65-73. PubMed ID: 27987591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib.
    Reck M; Mellemgaard A
    Biologics; 2015; 9():47-56. PubMed ID: 26170616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.
    Corral J; Majem M; Rodríguez-Abreu D; Carcereny E; Cortes ÁA; Llorente M; López Picazo JM; García Y; Domine M; López Criado MP
    Clin Transl Oncol; 2019 Sep; 21(9):1270-1279. PubMed ID: 30771085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma.
    Grohé C; Gleiber W; Haas S; Losem C; Mueller-Huesmann H; Schulze M; Franke C; Basara N; Atz J; Kaiser R
    Future Oncol; 2019 Aug; 15(23):2699-2706. PubMed ID: 31282758
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma.
    Metzenmacher M; Rizzo F; Kambartel K; Panse J; Schaufler D; Scheffler M; Azeh I; Hoiczyk M; Turki AT; Atz J; Buchner H; Hoffmann C; C Christoph D
    Future Oncol; 2021 Oct; 17(30):3965-3976. PubMed ID: 34287064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC.
    Westeel V; Schuette W; Urban T; Radonjic D; von Wangenheim U; Lorence RM; Reck M
    PLoS One; 2023; 18(10):e0292307. PubMed ID: 37847688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nintedanib plus Docetaxel after Immune Checkpoint Inhibitor Failure in Patients with Advanced Non-Small-Cell Lung Cancer: A Case Series.
    Hochmair MJ; Kolb R; Wurm R; Zach H; Bittner N
    Case Rep Oncol; 2022; 15(1):138-148. PubMed ID: 35350799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
    Jiang Q; Zhang NL; Ma DY; Tan BX; Hu X; Fang XD
    Medicine (Baltimore); 2019 Jun; 98(26):e16065. PubMed ID: 31261514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report.
    Espinosa Bosch M; Asensi Diez R; García Agudo S; Clopes Estela A
    Farm Hosp; 2016 Jun; 40(4):316-27. PubMed ID: 27571499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focus on Nintedanib in NSCLC and Other Tumors.
    Manzo A; Carillio G; Montanino A; Costanzo R; Sandomenico C; Rocco G; Morabito A
    Front Med (Lausanne); 2016; 3():68. PubMed ID: 28066768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy.
    Yamamoto N; Kenmotsu H; Goto K; Takeda K; Kato T; Takeda M; Horinouchi H; Saito I; Sarashina A; Tanaka T; Morsli N; Nakagawa K
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):685-694. PubMed ID: 30073583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancer.
    Auberle C; Gao F; Sloan M; Morgensztern D; Winkler L; Ward JP; Devarakonda S; Rearden TP; Govindan R; Waqar SN
    J Thorac Dis; 2024 Jun; 16(6):3782-3793. PubMed ID: 38983151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review.
    Garon EB; Visseren-Grul C; Rizzo MT; Puri T; Chenji S; Reck M
    Front Oncol; 2023; 13():1247879. PubMed ID: 37731641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.